Big pharma's devastating retreat from the UK

Big pharma's devastating retreat from the UK

Merck and AstraZeneca’s withdrawal from UK investment is a warning signal to Rachel Reeves – but is she listening? Asks Oliver Dean Both AstraZeneca and Merck’s decision to abandon their respective UK expansions is more than a corporate setback. It is a catastrophic loss of jobs, investment and future innovation and the public are now poorer as a result. Time and again, the government has boasted that it is pro-growth and pro-business, but unles…

‘A concerning pattern’: Pharma mulls UK divestments as government action lags in life sciences

Large pharma companies are rethinking their R&D and manufacturing pledges in the UK as tension deepens over what they say is a lack of government action to improve the life science investment space. Last week ...